Drugs / Wobenzym® plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01845558 | Feb 2013 → Sep 2014 | — | Mucos Pharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wobenzym plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01845558 ↗ |
| Modality | Protein / enzyme biologic | “an anti-inflammatory drug containing proteolytic enzymes” NCT01845558 ↗ |
| Route | Oral | “Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)” NCT01845558 ↗ |